What is LIMN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LIMN?

P/E (TTM) is n/a and 52-week range is $3.29 to $141.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LIMN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LIMN?

The company profile lists net income (TTM) near $-1.82B, EPS (TTM) near $-27.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Liminatus Pharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Palma, California, US, 67.2M shares outstanding, ISIN US53271X1081 when available from company profile and filing metadata.

Chartloom

Liminatus Pharma Inc (LIMN) Stock Analysis & Quote

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Website

liminatuspharma.com/

IPO

2021-05-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)